The Magnitude of what Belviq represents will not go unnoticed much longer, SV-flags
Investors. I know, I know reading a patent is boring, right? Lots of technical language! Well, may I suggest you make an effort to peruse the magnitude Belviq represents as Arena has been targeting the GPR119 receptor with respect to peptide YY. This is why one poster with asthma was surprised... why others are seeing vast improvements against diabetes... and of course weight loss...
But gang, what Belviq represents is a proprietary pool of technology Arena has into a target region that is turning out to have a wide range of medical applications. This is why I'm referring to Belviq as the next generation aspirin because its side benefits go well beyond obesity.
Now start thinking: Would Big Pharma want just a weight-loss drug, or would they really want the technology and proprietary information that goes much deeper and represents a range of potential medicines. This is where I see the true value of Arena. Belviq is their front-runner, but there's much more than the commoners who write trash-mag-internet articles grasp.
Dr. Vig.......come to the rescue to explain. Right now I see dollar signs after reading this info, I just don't know why, what, and when all the puzzle pieces fit together? I just know these are pieces to a bigger puzzle picture.
I may have to hold a couple of years longer to reap greater rewards.
I guess all we can do as investors is just keep buying as they keep manipulating, I know there is not much money in it as they pull it down while the other part of the market just goes up. The investors doing homework are going to make money in the lone run, this company is not going to be gone in a few years unless there is a buyout.
Investors. Here's a further example of what lies behind Belviq's technology and another range for a medical target:
"Inflammatory lung diseases that can be treated according to the invention include but are not limited to asthma, emphysema and pulmonary arterial hypertension (PAH). PAH is a life-threatening disease characterized by a progressive pulmonary vasculopathy leading to right ventricular hypertrophy; right heart failure occurs if left untreated. PAH shall be understood to encompass the following forms of pulmonary arterial hypertension described in the 2003 World Health Organization (WHO) clinical classification of pulmonary arterial hypertension: idiopathic PAH, familial PAH, PAH associated with other condition, and PAH associated with significant venous or capillary involvement. It shall be understood that in the present invention, inflammatory lung diseases that can be treated according to the invention can be included in embodiments individually or in any combination.
As used herein, the “inflammatory bowel disease” refers to a condition relating to abnormality of inflammation in the bowel. Inflammatory bowel diseases that can be treated according to the invention include but are not limited to Crohn's disease as may be enteritis, enterocolitis, Crohn's disease, granulomatous colitis, ileitis or Crohn's colitis and ulcerative colitis as may be ulcerative colitis, sigmoiditis, pancolitis and ulcerative proctitis. It shall be understood that in the present invention, inflammatory bowel diseases that can be treated according to the invention can be included in embodiments individually or in any combination."